Showing 1441-1450 of 2526 results for "".
- NeurOptics Launches Pupillometry Program at Vanderbilt University Medical Centerhttps://modernod.com/news/neuroptics-launches-pupillometry-program-at-vanderbilt-university-medical-center/2479015/NeurOptics recently announced that its NPi-200 pupillometers and the Neurological Pupil Index (NPi) are now being used in the Neurological Intensive Care Unit at Vanderbilt University Medical Center, in Nashville, Tennessee, as an important measurement for managing patients with brain injury.
- New Global Survey Underscores Need for Myopia Education and Evidence-Based Approacheshttps://modernod.com/news/new-global-survey-underscores-need-for-myopia-education-and-evidence-based-approaches/2478783/Recently released global survey results from CooperVision underscore a gap between the concern of eye care professionals and the understanding of parents regarding the growing myopia epidemic and the impact myopia can have on future eye health. Four in five eye care professionals (82%) worry that
- CDC Expands Negative COVID-19 Test Requirement to All Air Passengers Entering the United Stateshttps://modernod.com/news/cdc-expands-negative-covid-19-test-requirement-to-all-air-passengers-entering-the-united-states/2478761/The Centers for Disease Control and Prevention is expanding the requirement for a negative COVID-19 test to all air passengers entering the United States. Testing before and after travel is a critical layer to slow the in
- Turn Biotechnologies Licenses Technology that Aims to Unwind the Effects of Aging at a Cellular Levelhttps://modernod.com/news/turn-biotechnologies-licenses-technology-that-aims-to-unwind-the-effects-of-aging-at-a-cellular-level/2478747/Turn Biotechnologies announced that it has acquired the global rights for new technology that aims to reprogram cells to undo many of the effects of aging. The company licensed its epigenetic reprogramming of age (ERA) technology from Stanford University, where
- CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidatehttps://modernod.com/news/curevac-and-the-university-medical-center-mainz-start-phase-3-clinical-trial-for-covid-19-vaccine-candidate-cvncov-in-healthcare-workers/2478683/CureVac NV announced that the first participant in a clinical phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseaseshttps://modernod.com/news/gyroscope-therapeutics-and-the-university-of-pennsylvania-announce-research-agreement-to-develop-gene-therapies-for-serious-eye-diseases/2478679/Gyroscope Therapeutics announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edemahttps://modernod.com/news/unity-biotechnology-announces-first-patient-dosed-in-phase-1-study-of-ubx1325-in-diabetic-macular-edema/2478402/UNITY Biotechnology announced that the first patient has been dosed in a phase 1 study of UBX1325 in patients with diabetic macular edema (DME). “There is strong evidence of association between disease progression in DME and accumulation of senescent cells. There’s additional
- Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8
- Nearly Half of Physicians Believe It Will Take a Year to Get COVID-19 Under Controlhttps://modernod.com/news/nearly-half-of-physicians-believe-it-will-take-a-year-to-get-covid-19-under-control/2478174/The majority of physicians believe COVID-19 won’t be under control until January 2021, and nearly half (49%) expect it will take much longer to get the virus under control, according to a FierceHealthcare